|
Q4 FY2026
As of Jun 30, 2026
|
Q4 FY2025
As of Jun 30, 2025
|
Q4 FY2024
As of Jun 30, 2024
|
Q4 FY2023
As of Jun 30, 2023
|
Q4 FY2022
As of Jun 30, 2022
|
Q4 FY2021
As of Jun 30, 2021
|
Q4 FY2020
As of Jun 30, 2020
|
Q4 FY2019
As of Jun 30, 2019
|
|
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| CURRENT ASSETS | ||||||||
| Cash and cash equivalents | ||||||||
| Accounts receivable, net | ||||||||
| Crypto assets | ||||||||
| Other receivables, net | ||||||||
| Nonrelated Party | ||||||||
| Total other receivables, net | ||||||||
| Prepayments, net | ||||||||
| Loans receivable, net | ||||||||
| Total current assets | ||||||||
| NONCURRENT ASSETS | ||||||||
| Long-term investment, net | ||||||||
| Loans receivable, net | ||||||||
| Deposit for long-term investment | ||||||||
| Total noncurrent assets | ||||||||
| Total assets | ||||||||
| LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' EQUITY | ||||||||
| CURRENT LIABILITIES | ||||||||
| Convertible debentures | ||||||||
| Other payables and accrued liabilities | ||||||||
| Total current liabilities | ||||||||
| NONCURRENT LIABILITIES | ||||||||
| Convertible debentures | ||||||||
| Total noncurrent liabilities | ||||||||
| Total liabilities | ||||||||
| Class A Ordinary Shares subject to potential redemption, 66,668 and nil shares issued and outstanding as of June 30, 2026 and 2025, respectively | ||||||||
| SHAREHOLDERS' EQUITY | ||||||||
| Ordinary Share | ||||||||
| Common Class A | ||||||||
| Common Class B | ||||||||
| Total ordinary Share | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ||||||||
| Other comprehensive income | ||||||||
| Total SANGRIX INC. shareholders' equity | ||||||||
| NONCONTROLLING INTERESTS | ||||||||
| Total shareholders' equity | ||||||||
| Total liabilities, mezzanine equity and shareholders' equity | ||||||||
Loading...
